BioViva Treats First Patient with Gene Therapy to Reverse Aging

BioViva USA, Inc. has become the first company to treat a person with gene therapy to reverse biological aging, using a combination of two therapies developed and applied outside the United States of America. Testing and research on these therapies is continuing in BioViva’s affiliated labs worldwide.

BioViva CEO Elizabeth Parrish announced Biobthat the subject is doing well and has resumed regular activities. Preliminary results will be evaluated at 5 and 8 months with full outcome expected at 12 months. The patient will then be monitored every year for 8 years.

Gene therapy allows doctors to treat disease at the cellular level by inserting a gene into a patient’s cells instead of using the regular modalities of oral drugs or surgery. BioViva is testing several approaches to age reversal, including using gene therapy to introduce genes into the body.

Although not generally considered a disease, cellular aging is the leading cause of death in the developed world. Side effects like muscle wasting (sarcopenia), grey hair and memory loss are the well-known hallmarks.

And the aging cell is also responsible for the diseases of aging, including Alzheimer’s disease, heart disease and cancer. BioViva is leading the charge to treat the aging cell and reverse aging. “The aging cell is a key factor that has been overlooked for too long. Companies have put millions of dollars into treating the diseases of aging, such as dementia, frailty, kidney failure and Parkinson’s disease, and we still do not have a cure,” says Parrish.

Until now, no company had tried multiple gene therapies in one person. When asked why BioViva has done so, Parrish says, “Aging involves multiple pathways. We wanted to target more than one for a better outcome.”

Contact

Elizabeth Parrish

lparrish(at)BioVivaSciences(dot)com

http://www.biovivasciences.com